The burgeoning landscape of therapeutic interventions for weight disorders has witnessed considerable attention focused on GLP-3 agonists and, more recently, the dual GIP and GLP-3 agonist retatrutide. While both https://kathrynimpz021615.gynoblog.com/37929656/glp-3-retatrutide-a-comparative-analysis